JP2021528400A5 - - Google Patents

Info

Publication number
JP2021528400A5
JP2021528400A5 JP2020570158A JP2020570158A JP2021528400A5 JP 2021528400 A5 JP2021528400 A5 JP 2021528400A5 JP 2020570158 A JP2020570158 A JP 2020570158A JP 2020570158 A JP2020570158 A JP 2020570158A JP 2021528400 A5 JP2021528400 A5 JP 2021528400A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
patient
grem1
gremlin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020570158A
Other languages
English (en)
Japanese (ja)
Other versions
JP7565219B2 (ja
JP2021528400A (ja
Filing date
Publication date
Priority claimed from GBGB1809946.5A external-priority patent/GB201809946D0/en
Priority claimed from GBGB1815694.3A external-priority patent/GB201815694D0/en
Application filed filed Critical
Priority claimed from PCT/GB2019/051699 external-priority patent/WO2019243801A1/en
Publication of JP2021528400A publication Critical patent/JP2021528400A/ja
Publication of JP2021528400A5 publication Critical patent/JP2021528400A5/ja
Application granted granted Critical
Publication of JP7565219B2 publication Critical patent/JP7565219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020570158A 2018-06-18 2019-06-18 がんを予防及び治療するためのgremlin-1アンタゴニスト Active JP7565219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1809946.5A GB201809946D0 (en) 2018-06-18 2018-06-18 Prevention and treatment of cancer
GB1809946.5 2018-06-18
GBGB1815694.3A GB201815694D0 (en) 2018-09-26 2018-09-26 Prevention and treatment of cancer
GB1815694.3 2018-09-26
PCT/GB2019/051699 WO2019243801A1 (en) 2018-06-18 2019-06-18 Gremlin-1 antagonist for the prevention and treatment of cancer

Publications (3)

Publication Number Publication Date
JP2021528400A JP2021528400A (ja) 2021-10-21
JP2021528400A5 true JP2021528400A5 (enExample) 2022-06-10
JP7565219B2 JP7565219B2 (ja) 2024-10-10

Family

ID=67107908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570158A Active JP7565219B2 (ja) 2018-06-18 2019-06-18 がんを予防及び治療するためのgremlin-1アンタゴニスト

Country Status (21)

Country Link
US (1) US12162934B2 (enExample)
EP (1) EP3806898B1 (enExample)
JP (1) JP7565219B2 (enExample)
CN (1) CN112533632A (enExample)
AU (1) AU2019289176B2 (enExample)
BR (1) BR112020025661A2 (enExample)
CA (1) CA3102743A1 (enExample)
CL (1) CL2020003249A1 (enExample)
CO (1) CO2020015923A2 (enExample)
DK (1) DK3806898T3 (enExample)
ES (1) ES3054944T3 (enExample)
FI (1) FI3806898T3 (enExample)
HR (1) HRP20251604T1 (enExample)
IL (1) IL279347B1 (enExample)
LT (1) LT3806898T (enExample)
MX (1) MX2020013808A (enExample)
PL (1) PL3806898T3 (enExample)
PT (1) PT3806898T (enExample)
SG (1) SG11202012312UA (enExample)
SI (1) SI3806898T1 (enExample)
WO (1) WO2019243801A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
MX2020013808A (es) 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2022084400A1 (en) 2020-10-20 2022-04-28 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022152290A1 (en) * 2021-01-18 2022-07-21 Suzhou Transcenta Therapeutics Co., Ltd. Novel anti-gremlin1 antibodies
EP4304646A4 (en) * 2021-03-11 2025-05-28 Shanghai Jiao Tong University Methods for treating diseases with Gremlin1 antagonists
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
US20250257123A1 (en) 2022-04-20 2025-08-14 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2024026505A2 (en) * 2022-07-29 2024-02-01 Amit Patel Disruption of telocyte activity
CN120957750A (zh) * 2023-04-13 2025-11-14 苏州创胜医药集团有限公司 用于治疗癌症的涉及grem1拮抗剂的组合疗法
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
WO2002054940A2 (en) 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EP2824190A1 (en) 2003-09-09 2015-01-14 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) * 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
EP2826790B1 (en) 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody
EA201591762A1 (ru) * 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к grem1
CA2954298A1 (en) * 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技(上海)有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6709786B2 (ja) * 2014-12-11 2020-06-17 ベータ ファーマ,インコーポレイテッド Egfrモジュレーターとしての置換2−アミノピリミジン誘導体
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
TW201904577A (zh) * 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
CN111989099A (zh) * 2018-01-29 2020-11-24 贝塔制药有限公司 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
MX2020013808A (es) 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.

Similar Documents

Publication Publication Date Title
JP2021528400A5 (enExample)
JP2021514664A5 (enExample)
JP2020528750A5 (enExample)
JP2015517300A5 (enExample)
JP7249696B2 (ja) 抗cldn抗体並びにその医薬組成物および検出方法
KR20220012402A (ko) 항her3 항체-약물 콘주게이트
UA119036C2 (uk) Терапія раку, яка включає антитіло проти клаудину 18.2
CA2798778A1 (en) Anti-human trop-2 antibody having anti-tumor activity in vivo
MX2012011234A (es) Anticuerpos contra csf-1r.
FI3806898T3 (fi) Gremlin-1-antagonisti käytettäväksi syövän hoidossa
JP2021528047A5 (enExample)
ES2759329T3 (es) Anticuerpos contra la anfirregulina, composiciones que los comprenden y usos de los mismos
JP2017512759A5 (enExample)
JP2020505075A5 (enExample)
WO2015076425A1 (ja) 新規モノクローナル抗体
EP2561356A1 (en) MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2014068300A1 (en) Anti-s100a4 antibody molecules and their uses
JP2021517459A5 (enExample)
AU2015280436A1 (en) Antibodies that bind LGR4
JP2021512652A5 (enExample)
JP2024538148A5 (enExample)
JP2020537490A (ja) モノクローナル抗体抗fgfr4
JP2025511940A5 (enExample)
JP6041333B2 (ja) 抗腫瘍剤
JP2021524032A (ja) Gasp−1顆粒を標的とする結合性タンパク質及びキメラ抗原受容体t細胞並びにそれらの使用